80 related articles for article (PubMed ID: 20354277)
1. Matrix metalloproteinase- 9 polymorphisms in the diagnosis of prostate cancer. A preliminary experience.
Gil Ugarteburu R; Rivas del Fresno M; González Rodríguez I; González Arriaga P; López Cima F; Fernández Samoano A; Fernández García I; Benito García P; Muruamendiaraz Fernández V; Tardón A
Arch Esp Urol; 2010 Mar; 63(2):125-32. PubMed ID: 20354277
[TBL] [Abstract][Full Text] [Related]
2. Expression of matrix metalloproteinase-9 in prostate cancer. Preliminary experience.
González Rodríguez I; Rivas del Fresno M; Gil Ugarteburu R; González Arriaga P; López Cima F; Fernández Samoano A; Muruamendiaraz Fernández V; Fernández García I; Pérez-Carral JR; Tardón A
Arch Esp Urol; 2010 Mar; 63(2):119-24. PubMed ID: 20354276
[TBL] [Abstract][Full Text] [Related]
3. [Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population].
Zhang XM; Miao XP; Xiong P; Yu CY; Tan W; Qu SN; Sun T; Zhou YF; Lin DX
Ai Zheng; 2004 Nov; 23(11):1233-7. PubMed ID: 15522165
[TBL] [Abstract][Full Text] [Related]
4. Serum insulin level, disease stage, prostate specific antigen (PSA) and Gleason score in prostate cancer.
Lehrer S; Diamond EJ; Stagger S; Stone NN; Stock RG
Br J Cancer; 2002 Sep; 87(7):726-8. PubMed ID: 12232754
[TBL] [Abstract][Full Text] [Related]
5. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
6. Genetic polymorphisms of matrix metalloproteinases: susceptibility and prognostic implications for prostate cancer.
Dos Reis ST; Pontes J; Villanova FE; Borra PM; Antunes AA; Dall'oglio MF; Srougi M; Leite KR
J Urol; 2009 May; 181(5):2320-5. PubMed ID: 19303106
[TBL] [Abstract][Full Text] [Related]
7. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
Wong WW; Schild SE; Vora SA; Halyard MY
Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):24-9. PubMed ID: 15337536
[TBL] [Abstract][Full Text] [Related]
8. Associations of matrix metalloproteinase-9 protein polymorphisms with lymph node metastasis but not invasion of gastric cancer.
Tang Y; Zhu J; Chen L; Chen L; Zhang S; Lin J
Clin Cancer Res; 2008 May; 14(9):2870-7. PubMed ID: 18451255
[TBL] [Abstract][Full Text] [Related]
9. Functional -1562 C-to-T polymorphism in matrix metalloproteinase-9 (MMP-9) promoter is associated with the risk for oral squamous cell carcinoma in younger male areca users.
Tu HF; Wu CH; Kao SY; Liu CJ; Liu TY; Lui MT
J Oral Pathol Med; 2007 Aug; 36(7):409-14. PubMed ID: 17617834
[TBL] [Abstract][Full Text] [Related]
10. Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer.
Zhang L; Shi J; Feng J; Klocker H; Lee C; Zhang J
Prostate Cancer Prostatic Dis; 2004; 7(4):327-32. PubMed ID: 15356679
[TBL] [Abstract][Full Text] [Related]
11. Utility of incorporating genetic variants for the early detection of prostate cancer.
Nam RK; Zhang WW; Trachtenberg J; Seth A; Klotz LH; Stanimirovic A; Punnen S; Venkateswaran V; Toi A; Loblaw DA; Sugar L; Siminovitch KA; Narod SA
Clin Cancer Res; 2009 Mar; 15(5):1787-93. PubMed ID: 19223501
[TBL] [Abstract][Full Text] [Related]
12. The clinical potential of pretreatment serum testosterone level to improve the efficiency of prostate cancer screening.
Yano M; Imamoto T; Suzuki H; Fukasawa S; Kojima S; Komiya A; Naya Y; Ichikawa T
Eur Urol; 2007 Feb; 51(2):375-80. PubMed ID: 17005316
[TBL] [Abstract][Full Text] [Related]
13. TSP1 and MMP9 genetic variants in sporadic prostate cancer.
Sfar S; Saad H; Mosbah F; Gabbouj S; Chouchane L
Cancer Genet Cytogenet; 2007 Jan; 172(1):38-44. PubMed ID: 17175378
[TBL] [Abstract][Full Text] [Related]
14. Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.
Nam RK; Zhang WW; Trachtenberg J; Diamandis E; Toi A; Emami M; Ho M; Sweet J; Evans A; Jewett MA; Narod SA
J Clin Oncol; 2003 Jun; 21(12):2312-9. PubMed ID: 12805332
[TBL] [Abstract][Full Text] [Related]
15. Free, complexed, and total serum prostate-specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate.
Lerner SE; Jacobsen SJ; Lilja H; Bergstralh EJ; Ransom J; Klee GG; Piironen T; Blute ML; Lieber MM; Zincke H; Pettersson K; Peterson D; Oesterling JE
Urology; 1996 Aug; 48(2):240-8. PubMed ID: 8753736
[TBL] [Abstract][Full Text] [Related]
16. Prediagnostic prostate-specific antigen velocity and probability of detecting high-grade prostate cancer.
Krejcarek SC; Chen MH; Renshaw AA; Loffredo M; Sussman B; D'Amico AV
Urology; 2007 Mar; 69(3):515-9. PubMed ID: 17382156
[TBL] [Abstract][Full Text] [Related]
17. GSTP1 hypermethylation as a molecular marker in the diagnosis of prostatic cancer: is there a correlation with clinical stage, Gleason grade, PSA value or age?
Bastian PJ; Ellinger J; Schmidt D; Wernert N; Wellmann A; Müller SC; von Rücker A
Eur J Med Res; 2004 Nov; 9(11):523-7. PubMed ID: 15649863
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of antioxidant gene expression levels in circulating cancer cell clusters for the detection of prostate cancer in patients with prostate-specific antigen levels of 4-10 ng/mL and disease prognostication after radical prostatectomy.
Giesing M; Suchy B; Driesel G; Molitor D
BJU Int; 2010 Apr; 105(7):1000-10. PubMed ID: 19818074
[TBL] [Abstract][Full Text] [Related]
19. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
[TBL] [Abstract][Full Text] [Related]
20. Prostate stem cell antigen mRNA expression in preoperatively negative biopsy specimens predicts subsequent cancer after transurethral resection of the prostate for benign prostatic hyperplasia.
Zhao Z; Liu J; Li S; Shen W
Prostate; 2009 Sep; 69(12):1292-302. PubMed ID: 19462463
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
